Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

nowledge of our business, have broad experience and are committed to serving the best interests of all our shareholders. They have helped to build Amylin's leading portfolio of products and drug candidates and are a critical reason why the company is well positioned for significant future growth.

It is important to stress our conviction that the Icahn and Eastbourne objective to replace up to ten members of the Board would not serve the interests of the shareholders as a whole. Neither Icahn nor Eastbourne has articulated any business strategy for the company. We believe the ten nominees they have stated they intend to put forward collectively lack the experience and expertise necessary to maximize value for our shareholders and the commercialization expertise that many of our shareholders desire.

Recent Activities by Certain Shareholders

Icahn and Eastbourne had each stated their intention to nominate a slate of five directors for election to our Board at our upcoming annual meeting. On Monday, March 30, 2009, we learned that the Securities and Exchange Commission (the "SEC") granted Icahn and Eastbourne "no action" relief that would allow them to include each other's nominees on their proxy cards - thus, up to a total of ten nominees between them out of the twelve seats up for election.

While seeking the SEC's approval to do this, Icahn and Eastbourne had also raised concerns about provisions in our debt agreements. Eastbourne has publicly supported a lawsuit brought on March 27, 2009 by the San Antonio Fire & Police Pension Fund challenging debt acceleration provisions in two of our debt agreements, and Icahn is participating in that lawsuit.

Change-in-control provisions of the type found in our agreements are designed solely to protect the interests of creditors and are common in the marketplace. For example, of the 26 comparable biotechnology companies with publicly
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 2014 ... Industry” is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... ... - Aggressive acquisition ... Worldwide Clinical,Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team ... research organization with the announcement that it has closed the,acquisition of MediQuest, ...
... Cepheid (Nasdaq:,CPHD) today announced the appointment ... Associated Infections, Fred Tenover, Ph.D., as,Senior Director ... as a liaison,with the Infection Control community ... Consortium program., "The objective of the ...
... July 9 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ... and 25mg meclizine HCl tablets immediately. At,this time, Par ... product., Par marketed meclizine prior to an explosion ... Par has since qualified a new API source and,received ...
Cached Biology Technology:Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 2Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 3Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Par Pharmaceutical to Launch meclizine HCL Tablets 2
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3American Society of Human Genetics 2014 Annual Meeting 2
... Researchers from the John Innes Centre in Norwich, Great ... the FLORA project, have obtained genetically modified tomatoes rich ... class of flavonoids. These tomatoes, added to the diet ... extending the mice lifespan. The research has been published ...
... launcher that shall carry ESA,s GOCE Earth Explorer satellite ... in the guidance and navigation system of the launcher,s ... during the spacecraft,s launch preparation tests on 7 September ... of the launch. , The cause of the anomaly ...
... PHILADELPHIA Frank L. Meyskens, Jr., M.D., one ... chemoprevention, has been selected to receive the seventh ... Foundation Award for Excellence in Cancer Prevention Research. ... scientist for seminal contributions to the field of ...
Cached Biology News:Purple tomatoes: The richness of antioxidants against tumors 2Purple tomatoes: The richness of antioxidants against tumors 3Meyskens honored with AACR-Prevent Cancer Foundation award 2